{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-26-000043","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2026-07-30T20:01:59+00:00","discovered_at":"2026-07-30T20:03:00.757797+00:00","generated_at":"2026-07-30T20:03:24.968751+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Keros to receive $20M milestone from Takeda; will distribute 25% to stockholders","bullets":["$20M milestone triggered by first patient dosed in Phase 3 ELRiSE MDS trial of elritercept vs epoetin alfa for anemia in low-risk MDS.","Keros to distribute 25% of net cash proceeds from milestone to stockholders after receipt.","Under existing Takeda license (Jan 2025), Keros already received $200M upfront; total milestones could exceed $1.1B plus tiered royalties.","Phase 3 ELRiSE MDS trial is open-label, randomized, multicenter; follows positive Phase 2 signals in MDS with/without ring sideroblasts."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-26-000043","json":"https://secwatch.observer/filing/0001664710-26-000043.json","markdown":"https://secwatch.observer/filing/0001664710-26-000043.md","text":"https://secwatch.observer/filing/0001664710-26-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471026000043/0001664710-26-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471026000043/kros-20260730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T20:03:24.968751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}